Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease

A technology for inflammatory bowel disease and hyaluronic acid, applied in the direction of drug combinations, organic active ingredients, medical preparations containing active ingredients, etc., can solve problems such as slow degradation speed, inconvenient use for patients, and inability to maintain curative effect

Active Publication Date: 2011-07-06
HOLY STONE HEALTHCARE CO LTD
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Among them, only hyaluronic acid or its salts with a weight average molecular weight (Mw) of 600,000 to 1,200,000 Daltons (Da) is used. Although it has the characteristics of rapidly spreading to treat inflammatory bowel disease, its degradation speed after implantation Unfortunately, (refer to Thorn-ton MH, Johns DB, Campeau JD, Hoehler F, diZerega GS. Human Reproduction 1998; 13: 1480-85.), but cannot maintain the curative effect of enough time, clinically, for the use of patients is very inconvenient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
  • Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease
  • Mixture of hyaluronic acid for treating and preventing inflammatory bowel disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1-1: Summary

[0036] This test uses the animal model of inflammatory bowel disease to evaluate the efficacy of the sample IBD98 in the animal body. The rats in the prevention group were given IBD98 through the anus first, and then administered trinitrobenzenesulfonic acid (TNBS) to induce enteritis lesions, and then administered through the anus for 3 consecutive days For the sample IBD98, the control group was only given TNBS to induce enteritis lesions, and observed for 3 days. All rats were sacrificed on the 4th day after TNBS administration to examine the clinical lesions, and blood was collected before administration and at the time of sacrifice to detect inflammatory indicators. The results showed that the average range of colonic inflammation in the prevention group and the control group was 3.9 cm and 4.3 cm, respectively, and there was no significant difference between the two. There were significant differences in the concentrations of TNF-α (Tumor Necrosis F...

Embodiment 2

[0064] 2-1: Summary

[0065] This test uses the animal model of inflammatory bowel disease to evaluate the efficacy of the sample IBD98 in the animal body. The experimental rats are first administered with trinitrobenzenesulfonic acid (TNBS) through the anus to induce enteritis lesions, and then three days later, the samples IBD98 are administered through the anus. (Treatment group) and buffered phosphate saline (PBS) (control group) were treated continuously for seven days, and then the rats were sacrificed to examine the clinical lesions. The results showed that the colonic inflammation range of the rats in the treatment group injected with the sample IBD98 was about 1.25 cm on average, The average range of inflammation in the colon of rats administered with buffered phosphate saline in the control group was about 1.875 cm, and the relative degree of recovery compared with the treatment group and the control group was 33%, showing that the use of IBD98 to treat inflammatory b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A mixture of hyaluronic acid for treating and preventing inflammatory bowel disease, includes at least two or more hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Crohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.

Description

technical field [0001] The present invention provides a hyaluronic acid mixture used for the treatment and prevention of inflammatory bowel disease (IBD), especially refers to the use of at least two or more than two kinds of hyaluronic acid with different weight average molecular weight (Mw) and different The rheological hyaluronic acid is mixed, and the resulting hyaluronic acid mixture has suitable adhesion, insulation, tissue scaffolding function and curative effect time, and is used to target inflammatory bowel diseases (including ulcerative colitis, Crohn's disease, Crohn's disease) treatment and prevention, to achieve both quick and slow effects of treatment. Background technique [0002] Polymer hyaluronic acid (hyaluronan), also known as "hyaluronic acid", covers hyaluronic acid (hyaluronic acid), its pharmacologically acceptable salt (hyaluronate) or generally referred to as "hyaluronic acid", and is referred to as "HA", hereinafter Collectively referred to as hya...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/728A61P1/00A61P1/04
CPCA61K31/728A61K45/06A61P1/00A61P1/04A61K2300/00
Inventor 吴宗忠
Owner HOLY STONE HEALTHCARE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com